All News
No Great Options for Treating VEXAS
MedPage Today
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
Read Article
Pharmacologic Efficacy in Still's Disease
A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.
Cutoffs for Systemic Juvenile Arthritis Disease Activity Score
An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10), a disease activity measure distinguish patients with inactive disease, minimal disease activity, moderate disease activity, and high disease activity.
Read Article
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn
Dr. Antoni Chan synovialjoints ( View Tweet)
NEW biomarkers in #MAS
1️⃣ IL-18 (available at some 🏥)⭐️
2️⃣ S100A12
3️⃣ CXCL9/10
🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder!
🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷
#macrophage
#EULAR2024
#genetics
#rheumx https://t.co/Uot3JjrWs8
Links:
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
Potential efficacy of JAK inhibitors in VEXAS syndrome
#EULAR2024
NZ https://t.co/HziLUgo1gA
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
#Behcet’s #syndrome is increasing in the UK
? ⬆️ Detection
? Changing population demographics
? Other reasons
Poster discussion POS0258
#EULAR2024 @RheumNow @eular_org
@Pr1yankaC https://t.co/SEzmJnFMhM
Links:
Janet Pope Janetbirdope ( View Tweet)
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 !
Amazing pictures to explain cellular level pathophysiology!
Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Bella Mehta bella_mehta ( View Tweet)
STAR responder may be the way to go! Less placebo effect than CREST.
Better in patients with low systemic activity. https://t.co/mMYOKfG2gS
Links:
Bella Mehta bella_mehta ( View Tweet)
FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/dZ21V2cKwR https://t.co/QADVP2w3Tz
Dr. John Cush RheumNow ( View Tweet)
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk
Links:
Dr. John Cush RheumNow ( View Tweet)
No Great Options for Treating VEXAS
For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ
Dr. John Cush RheumNow ( View Tweet)
Study of 187 Oligoarticular JIA pts - Remission was achieved w/ DMARDs in 65.8%; predictors of nonresponse (DMARD resistance) - Elevated CRP (> 1.1 mg/dL' OR 1.3) & and high JADAS-71 at Dx (> 15.8; OR 1.7) https://t.co/oPajnplXUL https://t.co/TnrknASCzb
Dr. John Cush RheumNow ( View Tweet)
Cutoffs for sJADAS10
An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the sJADAS10, a disease activity measure distinguish patients with ID, MiDA, MoDA, HDA.
https://t.co/A0kIqiOWFE https://t.co/zShqs781W1
Dr. John Cush RheumNow ( View Tweet)
Study of 187 Oligoarticular JIA pts - Remission was achieved w/ DMARDs in 65.8%; predictors of nonresponse (DMARD resistance) - Elevated CRP (> 1.1 mg/dL' OR 1.3) & and high JADAS-71 at Dx (> 15.8; OR 1.7) https://t.co/tuO7UsEfrL https://t.co/KGcdBtneQt
Dr. John Cush RheumNow ( View Tweet)
BSR presented (at the 2024 annual BSR meeting) new guidelines for the management of Behçet's disease - how to manage skin lesions, mouth ulcers, genital ulcers, serious eye, CNS & vascular involvement https://t.co/SFM4NJ48fH
Dr. John Cush RheumNow ( View Tweet)
British Society for Rheumatology (BSR) presented (at the 2024 annual BSR meeting) new guidelines for the management of Behçet's disease - how to manage skin lesions, mouth ulcers, genital ulcers, serious eye, CNS & vascular involvement https://t.co/d0bjKuubym https://t.co/lqoTeTGqZ7
Dr. John Cush RheumNow ( View Tweet)
'Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases’ - a 6 center consortium will study if JAKi (filgotinib) is effective and safe in 3 rare disorders -- Behcets, inflammatory myositis & IgG4 related disease. https://t.co/UyZM4VNSY2 https://t.co/D2D1tdygS4
Dr. John Cush RheumNow ( View Tweet)
Renal Dz in 44 AOSD (Stills)pts-mean age 38; 28 w/ renal onset after Dx. 36 renal Bx showed amyloidosis (25%), collapsing glomerulopathy (11%), thrombotic microangiopathy (11%), IgA nephropathy (9%), minimal change (7%). Renal assoc w/ 6 deaths; 4 ESRD https://t.co/tQykmjNIIb https://t.co/n0xgi6uF6D
Dr. John Cush RheumNow ( View Tweet)
Systemic Score Predicts Still's Disease Severe Complications
A multinational study of adults with Still's disease found that calculating their systemic score at baseline significantly predicted the patients risk for life-threatening outcomes.
https://t.co/YB7EcWFruE https://t.co/Vcql5tZHOk
Dr. John Cush RheumNow ( View Tweet)
